Erratum: Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients (Journal of the National Cancer Institute (2017) 109 (9) DOI: 10.1093/jnci/djx029);Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients

Journal of the National Cancer Institute

Volumn 109, Issue 9, 2017, Pages 436-

  Denis, Fabrice ^a,b   Lethrosne, Claire ^c   Pourel, Nicolas ^d   Molinier, Olivier ^e   Pointreau, Yoann ^a   Domont, Julien ^a   Bourgeois, Hugues ^a   Senellart, Hélène ^f   Trémolières, Pierre ^g   Lizée, Thibaut ^g   Bennouna, Jaafar ^f   Urban, Thierry ^h   El Khouri, Claude ⁱ   Charron, Alexandre ^a   Septans, Anne Lise ^g   Balavoine, Magali ^g   Landry, Sébastien ^a   Solal Céligny, Philippe ^f   Letellier, Christophe ^b  

^a Inter regional Institute of Cancerology Jean Bernard   (France)

^b Unitéde Recherche Associée au Centre National de la Recherche Scientifique 230   (France)

^c CENTRE HOSPITALIER   (France)

^d INSTITUT SAINTE CATHERINE   (France)

^e CENTRE HOSPITALIER DU MANS   (France)

^f Institut de cancerologie de l'Ouest Rene Gauducheau   (France)

^g Institut de Cancerologie de l'Ouest   (France)

^h ANGERS UNIVERSITY HOSPITAL   (France)

ⁱ Centre Catherine de Sienne   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; COUGHING; DISEASE EXACERBATION; DYSPNEA; E-MAIL; FATIGUE; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LARGE CELL CARCINOMA; LOSS OF APPETITE; LUNG CANCER; MAINTENANCE CHEMOTHERAPY; MALE; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; ONCOLOGIST; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RELAPSE; SENSITIVITY AND SPECIFICITY; SMALL CELL LUNG CANCER; SQUAMOUS CELL CARCINOMA; STEREOTACTIC RADIOSURGERY; X-RAY COMPUTED TOMOGRAPHY; CANCER STAGING; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; HEALTH SURVEY; INTERNET; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; SELF REPORT; STATISTICS AND NUMERICAL DATA; TIME FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; DIAGNOSTIC SELF EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNET; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SELF REPORT; TIME FACTORS;

EID: 85021389063     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djy020     Document Type: Erratum

References (22)

1. Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3488–3515.
2. Meregaglia M, Cairns J. Economic evaluations of follow-up strategies for cancer survivors: A systematic review and quality appraisal of the literature. Expert Rev Pharmacoecon Outcomes. 2015;15(6):913–929.
3. Bakitas MA, Tosteson TD, Li Z, et al. Early versus delayed initiation of concurrent palliative oncology care: Patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol. 2015;33:1438–1445.
4. Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. J Clin Oncol. 2015;34:557–565.
5. Walsh GL, O’Connor M, Willis KM, et al. Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg. 1995; 60:1563–1570.
6. Gilbert S, Reid KR, Lam MY, et al. Who should follow up lung cancer patients after operation? Ann Thorac Surg. 2000;69:1696–1700.
7. Westeel V, Choma D, Clement F, et al. Relevance of an intensive postoperative follow-up after surgery for non-small cell lung cancer. Ann Thorac Surg. 2000;70:1185–1190.
8. Selby JV, Beal AC, Frank L. The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda. JAMA. 2012;307:1583–1584.
9. Basch E, Artz D, Dulko D, et al. Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol. 2005;23:3552–3561.
10. Basch E. Patient-reported outcomes harnessing patients’ voices to improve clinical care. N Engl J Med. 2017;12:105–108
11. Denis F, Viger L, Charron A, et al. Detecting lung cancer relapse using self-evaluation forms weekly filled at home: The sentinel follow-up. Support Care Cancer. 2014;22:79–85.
12. Denis F, Viger L, Charron A, et al. Detection of lung cancer relapse using self-reported symptoms transmitted via an Internet Web application: Pilot study of the sentinel follow-up. Support Care Cancer. 2014;22:1467–1473.
13. Denis F, Yossi S, Septans AL, et al. Improving survival in patient treated for a lung cancer using self-evaluated symptoms reported via a web application. Am J Clin Oncol. 2015; in press.
14. Edge SB, Compton CC. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474.
15. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
16. Filleron T, Gal J, Kramar A. Designing group sequential randomized clinical trials with time to event end points using a R function. Comput Methods Programs Biomed. 2012;108(1):113–128.
17. Carrier M, Lazo-Langner A, Shivakumar S, et al. Screening for occult cancer in unprovoked venous thromboembolism. N Engl J Med. 2015;373:697–704.
18. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.
19. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733–742.
20. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31: 2895–2902
21. Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: Results from Eastern Cooperative Oncology Group Study 5592.J Clin Oncol. 2003;21:1536–1543.
22. Cella D1, Herbst RS, Lynch TJ, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol. 2005;23: 2946–2954.